Scientists are developing a groundbreaking universal vaccine using artificial intelligence (AI) that could provide protection against entire families of viruses to prevent future pandemics. The innovative jab, a world-first creation by experts at Cambridge and Southampton universities, is designed to target a “super antigen” common to various viruses, making it impossible for them to evade immunity. This approach aims to address the issue of viruses evolving over time, rendering current vaccines less effective.
The vaccine development process involved feeding the AI with global data on past viral mutations to identify the essential components necessary for the survival of similar viruses. The trial results have shown that the vaccine, which has already undergone the first phase successfully, is safe and effective. The second phase of the trial is set to launch soon.
Chief investigator Prof Saul Faust emphasized the importance of this new class of universal vaccines, highlighting their ability to protect against multiple variants simultaneously and potentially against emerging viruses. The goal is to save lives, prevent lockdowns, and safeguard the economy by proactively addressing viral threats.
The universal Sarbeco coronavirus vaccine, developed in partnership with biotechnology company DIOSynVax, has shown promising results in healthy volunteers aged 18 to 50 during the initial trial phase. Administered as a DNA vaccine using a needle-free method, the vaccine induced a strong immune response against not only SARS-CoV-2 but also related bat viruses that pose a potential threat to humans.
The researchers are optimistic about the vaccine’s potential to revolutionize viral protection by offering broad immunity against various virus strains, including those that have not yet emerged. The study, sponsored by University Hospital Southampton NHS Foundation Trust, marks a significant advancement in the quest for lasting viral protection.
Prof Marian Knight, the scientific director for the National Institute for Health and Care Research (NIHR) Infrastructure, hailed the success of the AI-designed super-antigen trial as a pivotal achievement in enhancing viral defense capabilities. The ongoing efforts to develop this innovative vaccine represent a proactive approach to combating future viral threats.
